Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T22:23:35.046Z.
Consensus retrieved: 2026-10-06T16:04:19.528Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T22:23:35.046Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: eb6c183c54b52a3f5be7b88cd35f52a8db6123751fb387d2cb2c86d403628cdc
Forward PE Ratio (N/A) = Dated Quote Price ($4.32) / Consensus Forward EPS ($-0.70)
FORWARD PE RATIO
N/A
Rezolute, Inc.
Market Cap
$415.98M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Rezolute, Inc. (RZLT) | $415.98M | N/A |
| Senseonics Holdings, Inc. (SENS)vs › | $416.27M | N/A |
| Editas Medicine, Inc. (EDIT)vs › | $418.95M | N/A |
| Prothena Corporation plc (PRTA)vs › | $419.87M | 72.91 |
| MapLight Therapeutics, Inc. (MPLT)vs › | $411.21M | N/A |
| Strata Critical Medical, Inc. (SRTA)vs › | $411.00M | N/A |
| Tilray Brands, Inc. (TLRY)vs › | $422.72M | N/A |
| Tectonic Therapeutic, Inc. (TECX)vs › | $422.86M | N/A |
| NeoGenomics, Inc. (NEO)vs › | $424.10M | 90.32 |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $406.58M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2027-06-30
At the dated quote price of $4.32, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-06-30 | $-0.70 | $-0.82 – $-0.62 | 7 | n/m |
| 2028-06-30 | $-0.52 | $-0.59 – $-0.45 | 6 | n/m |
| 2029-06-30 | $-0.88 | $-8.22 – $2.75 | 7 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
